Semaglutide nume commerciale: Wegovy, Ozempic e la differenza che conta

Why does semaglutide have more than one commercial name?

Pharmaceutical licensing ties a brand name to a specific indication, dose range and formulation. Novo Nordisk developed semaglutide first as a diabetes treatment and launched it under the name Ozempic, available as a weekly injection up to 1mg (later 2mg for diabetes). When clinical trials demonstrated significant weight reduction in adults with obesity, a separate regulatory dossier was submitted for a higher-dose version. The MHRA approved Wegovy as a distinct brand for weight management, with its own dosing schedule running up to 2.4mg weekly, and now 7.2mg following the 2026 approval. This is why the commercial name matters in practice: semaglutide's licensed use in each form is not a formality but a legal and clinical boundary. A prescriber considering weight management treatment for you works within the Wegovy licence, not Ozempic's.

There is also Rybelsus, oral semaglutide approved for type 2 diabetes at tablet doses of 3mg, 7mg and 14mg. This is a third commercial name, but again it is a diabetes product. Searching for semaglutide's commercial name and landing on Rybelsus information would not give you the right weight-loss picture, and understanding how Wegovy functions as a commercial product is a useful way to avoid that confusion. The common name versus brand name distinction is genuinely worth understanding before you make any decisions.

What exactly is Wegovy and how does it work as a commercial product?

Wegovy is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, slows the rate at which the stomach empties, and reduces appetite over time. The weekly injection comes as a pre-filled pen. The titration schedule starts at 0.25mg and steps up, typically every four weeks under prescriber guidance, until reaching the maintenance dose the prescriber determines is appropriate for you. The MHRA's approval of a dedicated 7.2mg weekly pen in April 2026 extended the ceiling, with trial data at that dose reporting around 20.7% average weight loss over 72 weeks.

The oral Wegovy tablet, approved by the MHRA on 11 June 2026, uses the same active ingredient with an absorption enhancer so it can work through the gut wall. It starts at 1.5mg daily and titrates through 4mg and 9mg to a 25mg maintenance dose. Clinical trial data (OASIS 4) showed roughly 13.6% average weight loss over 64 weeks compared with around 2.4% on placebo; among participants who adhered fully, the figure was closer to 17%. The tablet requires no refrigeration, which is one practical difference from the injection. NHS guidance on semaglutide as a medicine covers both forms at the patient level and is a useful starting point.

Does the commercial name change how it is prescribed or accessed?

Yes, in a meaningful way. The prescriber is bound by the product's licence. Ozempic cannot lawfully be prescribed for weight loss by a responsible prescriber in the normal course of practice, because its UK licence covers type 2 diabetes. Wegovy, in its injection and tablet forms, is the correct route for adults seeking weight management treatment. Both are prescription-only medicines, which means no version of semaglutide under any commercial name can be lawfully supplied in the UK without a valid prescription from a qualified prescriber. The MHRA has issued warnings about pens sold online that contain unknown substances, the counterfeit market specifically exploits the gap between demand and legitimate supply.

For those considering the cost of treatment, it is worth knowing that what Wegovy costs privately varies by dose and provider, and that a legitimate private price always includes the prescription as part of the process. Understanding the commercial name is the first step; understanding the supply chain is the second. The NICE appraisal of Wegovy (TA875) sets the NHS eligibility framework, which is separate from the private route.

What if you feel cold or notice unexpected effects after starting treatment?

Semaglutide's side-effect profile is well documented under both commercial names because the mechanism is the same. Gastrointestinal symptoms (nausea, loose stools, constipation, indigestion) are the most common, typically appearing when the dose steps up and settling over days to a couple of weeks. Less expected effects, such as feeling persistently cold, sometimes prompt questions; there is published patient reporting on feeling cold on Wegovy, and while the mechanism is not fully established, it is a recognised experience worth discussing with your prescriber.

Serious symptoms require urgent attention regardless of which commercial name is on the pen or packet. Severe stomach pain that radiates to the back, persistent vomiting leading to dehydration, or signs of an allergic reaction are reasons to seek medical help straight away. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows anyone to report a suspected side effect and is worth bookmarking when you start treatment. Your prescriber and the Patient Information Leaflet inside the box are the authoritative sources on what to watch for at your specific dose, the leaflet arrives in the same plain, untracked packaging as the pen itself, and the DPD tracking link lands in your inbox before the box does.

If you want to explore whether semaglutide treatment under its UK commercial name could be right for you, the next step is a clinical conversation rather than a search. Check your eligibility through our free consultation and a GPhC-registered prescriber will review your details the same day.